Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 32 Vavilov St., Moscow 119991, Russia.
Chem Biol Drug Des. 2012 Dec;80(6):947-52. doi: 10.1111/cbdd.12047. Epub 2012 Oct 9.
A series of new 5'-O-carbamate prodrugs of AZT have been prepared. The stability in biological media, anti-HIV properties and pharmacokinetic parameters in dogs were evaluated. The compounds display moderate anti-HIV activity in cell culture. After oral administration of carbamate IV in dogs, both intact prodrug IV and released AZT were discovered in dog blood. Pharmacokinetic parameters of the compound IV were estimated. Half-life (T(1/2)) of AZT released after oral administration of IV in dogs was close to that after administration of AZT itself, and time to the maximum concentration (T(max)) of AZT released from IV was two and three times longer compared with that of AZT and H-phosphonate AZT, respectively. Acute toxicity was more than five times less if compared with AZT. As a result, we consider this series of carbamate derivatives of AZT as perspective for development of anti-HIV agents.
已经制备了一系列新的 AZT 5'-O-氨基甲酸酯前药。评估了它们在生物介质中的稳定性、抗 HIV 特性和犬体内的药代动力学参数。这些化合物在细胞培养中表现出中等的抗 HIV 活性。在狗中口服氨基甲酸酯 IV 后,在狗的血液中发现了完整的前药 IV 和释放的 AZT。估计了化合物 IV 的药代动力学参数。与 AZT 本身给药相比,狗口服 IV 后释放的 AZT 的半衰期 (T(1/2)) 相近,从 IV 释放的 AZT 的最大浓度 (T(max)) 分别比 AZT 和 H-膦酸酯 AZT 长两倍和三倍。与 AZT 相比,急性毒性降低了五倍以上。因此,我们认为这一系列 AZT 的氨基甲酸酯衍生物是开发抗 HIV 药物的有前途的候选物。